comparemela.com

Latest Breaking News On - Poor prognosis - Page 1 : comparemela.com

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational.

Taiwan
Hong-kong
Minnesota
United-states
Macau
China
Stockholm
Sweden
Olmsted-county
Japan
Cambridge
Cambridgeshire

Biogen Inc.: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational

Taiwan
Japan
China
United-states
Minnesota
Hong-kong
Olmsted-county
Stockholm
Sweden
Macau
Cambridge
Cambridgeshire

Florida zoo euthanizes beloved 15-year-old tiger after learning of 'heartbreaking' cancer prognosis

“As we sadly announce his passing, we will soon be announcing something much more uplifting that will only add to this magnificent cat’s legacy,” the zoo said.

Miami
Florida
United-states
San-francisco-zoo
Species-survival-plan
Sumatran-tiger
Zoo-miami
Pleen-cancer
Poor-prognosis

Utilizing Biomarkers in Cancer Prevention, Diagnosis, and Treatment

In this interview, Grace Liu from Sino Biological discusses the crucial role of biomarkers in cancer prevention and diagnosis and how they can help guide treatment decisions.

Houston
Texas
United-states
Baylor-college-of-medicine
Maria-osipova
Drimafilm-shutterstock
Sino-biological-inc-oct
Sino-biological-inc
Houston-methodist-research-institute
Sino-biological-us-inc
Sponsored-content
Grace-liutechnical-account-managersino

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.

France
Salomon-manier
International-myeloma-society
Centre-hospitalier-universitaire-de-lille
International-staging-system
Annual-meeting
Cilta-cel
Cart-cell-therapy
Car-t
Multiple-myeloma
Myeloma
Poor-prognosis

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.